Gilgamesh Scoops $14m from NIDA to Develop Safer Ibogaine Analog for Opioid Use Disorder
Psychedelic drug developer Gilgamesh Pharmaceuticals has scooped a grant worth $14m from the National Institute on Drug Abuse (NIDA) to develop its ibogaine analog, GM-3009, for opioid use disorder (OUD). The company hopes that the compound will prove to be ‘cardiac-safe’, alluding to concerns around ibogaine’s cardiotoxicity which may represent a barrier to achieving FDA approval for the drug.
Here, we speak to Gilgamesh's Co-Founder and Chief Scientific Officer, Andrew Kruegel, about the news...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In